Study title: Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging : Frühwald MC, Rickert CH, O'Dorisio MS, Madsen M, Warmuth-Metz M, Khanna G, Paulus W, Kühl J, Jürgens H, Schneider P, Müller HL; Clin Cancer Res. 2004 May 1;10(9):2997-3006
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Diagnosis [E01] | |||||
| Brands: Please see report, Please see report, Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report, Please see report, Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: (111In) INDIUM CHLORIDE/PENTETREOTIDE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | Y | |